Alendronate Sodium Tablet
Product Images NDC 69097-224

9 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 69097-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Structure)

1 (Structure)
Chemical structure diagram of alendronate sodium, showing the molecular arrangement including amino, carbon, phosphate groups, and sodium with associated waters of hydration (3H2O).*
FDA Label Image

Fracture (Fig1 1)

Fracture (Fig1 1)
A line graph showing the cumulative incidence of hip fractures over 36 months in a three-year study of patients with radiographic vertebral fractures at baseline. The graph compares two groups: one receiving placebo and the other receiving alendronate sodium, with cumulative incidence percentage on the y-axis and time in months on the x-axis.*
FDA Label Image

Treatment (Figure1 2)

Treatment (Figure1 2)
A bar chart comparing the mean percent increase in bone mineral density (BMD) relative to placebo in three anatomical sites: lumbar spine, femoral neck, and trochanter. The chart shows data for two groups labeled U.S. and Multinational, with error bars indicating standard error.*
FDA Label Image

Postmenopausal (Figure1 3)

Postmenopausal (Figure1 3)
A pair of line graphs comparing bone mineral density (BMD) mean percent change from baseline over 36 months in US and multinational studies. Each graph shows data for Alendronate Sodium 10 mg versus placebo, with the Alendronate groups demonstrating an increase in BMD over time and placebo groups showing no significant change.*
FDA Label Image

5 (Fig 1 4)

5 (Fig 1 4)
Two bar graphs titled "Osteoporosis Prevention Studies in Postmenopausal Women" showing change in bone mineral density (BMD) from baseline in a 2-year and a 3-year study. Both compare mean percentage change in BMD plus standard error for Alendronate Sodium 5 mg/day versus placebo at lumbar spine, femoral neck, trochanter, and total body sites.*
FDA Label Image

6 (Fig1 5)

6 (Fig1 5)
A bar chart titled 'Studies in Glucocorticoid-Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year' showing mean percentage increase in bone mineral density (BMD) at lumbar spine, femoral neck, and trochanter. Two groups compared: U.S. and Multinational, with the Multinational group showing generally higher BMD increases.*
FDA Label Image

7 (Fig 1 6)

7 (Fig 1 6)
A line graph showing the effect of Alendronate Sodium 40 mg/day compared to placebo and Etidronate 400 mg/day on serum alkaline phosphatase levels over 6 months in Paget's disease of bone. The graph depicts mean percent changes from baseline with standard error, differentiating results from multinational and U.S. studies, with sample sizes noted for each group.*
FDA Label Image

35mg (Ale 223 16)

35mg (Ale 223 16)
Packaging label for Alendronate Sodium Tablets, USP 35 mg by Cipla USA Inc. The label states the product is once weekly and includes instructions for tablet removal from the blister. The label also provides dosage details, storage conditions, and regulatory information for this prescription oral tablet package containing one blister of 4 tablets.*
FDA Label Image

70mg (Ale 224 16)

70mg (Ale 224 16)
Box packaging label for Alendronate Sodium Tablets USP, 70 mg, once weekly oral tablets by Cipla USA Inc. The label includes dosing instructions, pharmacist dispensing advice, and a 1 blister pack containing 4 tablets. The NDC 69097-224-16 and barcode are visible, along with guidance on removing tablets from the blister pack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.